We report the case of a woman in her 50s who underwent, 5 years prior, a total gastrectomy after neoadjuvant chemotherapy for diffuse-type gastric cancer diagnosed during a workup for isolated gastric primary light chain (AL) amyloidosis. At the time of diagnosis, immunoglobulins light chain measurements and bone marrow biopsy were performed to rule out multiple myeloma and came back normal. Three years later, the patient developed systemic amyloidosis involving the heart and the lungs, after which she developed multiple myeloma. Isolated amyloid deposits in the stomach are a rare finding. While AL amyloidosis is frequently found in concomitance with multiple myeloma, late progression of primary AL amyloidosis to systemic amyloidosis and multiple myeloma is uncommon.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230937 | PMC |
| http://dx.doi.org/10.1136/bcr-2022-252786 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is Bone Marrow Trephine Biopsy Necessary in Multiple Myeloma Patients at Diagnosis?
Clin Lymphoma Myeloma Leuk
December 2024
Department of Hematology, University Hospital Marqués de Valdecilla/IDIVAL, Santander, Spain; University of Cantabria, Santander, Spain. Electronic address:
Multiple myeloma (MM) diagnosis requires ≥10% plasma cell (PC) infiltration in the bone marrow (BM), detected by bone marrow aspiration (BMA) or biopsy (BMB). We evaluated the concordance of these 2 techniques in 189 patients. In 43 cases (23%), the techniques were discordant, 10 due to poor sample quality.
View Article and Find Full Text PDFBortezomib With High-dose Melphalan Conditioning Regimen in Newly Diagnosed Multiple Myeloma Patients: Long-term Follow-up.
In Vivo
December 2024
Division of Hematology, Department of Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
Background/aim: Autologous stem cell transplantation (ASCT) is the standard strategy after induction therapy for newly diagnosed transplant-eligible multiple myeloma. High-dose melphalan (HDM) conditioning has been the recommended treatment regimen for a long time. No other conditioning regimen has been proven safer and more effective.
View Article and Find Full Text PDFSolitary extramedullary plasmacytoma in the hilar region: A case of minimal marrow involvement in an elderly male.
Int J Surg Case Rep
December 2024
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address:
Introduction And Importance: Solitary extramedullary plasmacytoma (SEP) is a rare plasma cell neoplasm, constituting around 3 % of plasma cell malignancies. SEP typically presents as a single tumor, either in bone or soft tissue, without systemic disease, and is often misdiagnosed due to its nonspecific symptoms. Diagnosis requires biopsy and extensive imaging studies to exclude multiple myeloma and other malignancies.
View Article and Find Full Text PDFInternational Staging System Status and Trend of Relapse in Multiple Myeloma Cases in a Tertiary Level Health Care.
Mymensingh Med J
January 2025
Dr Md Mahbubul Alam, Junior consultant (Medicine), National Gastroliver Institute and Hospital, Dhaka, Bangladesh; E-mail:
Multiple myeloma (MM) is a haematological neoplasm of mature B-cell lineage origin. It is characterized by abnormal clonal proliferation of plasma cells and presence of monoclonal protein in serum and / or urine. This study was conducted to observe the International Staging System (ISS) status and trends of relapse.
View Article and Find Full Text PDFEconomic evaluation of critically ill adult CAR-T cell recipients-analysis from a healthcare payer perspective.
Med Klin Intensivmed Notfmed
December 2024
Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
Background: CAR-T cell (chimeric antigen receptor T) therapy is now part of standard of care treatment of B‑cell lineage malignancies. Although it is an effective treatment, it comes along with adverse side effects and toxicities that may require intensive care therapy. The costs related to critical care therapy in critically ill patients after CAR‑T administration have not been evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!